Skip to main content
Caplight Logo









TolerogenixX GmbH

TolerogenixX GmbH

Private
HeidelbergHealthcare & Life Scienceshttps://www.tolerogenixx.com/

Last Round

Series A

Jul 6, 2023

Total Funding Raised

$12.63M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

TolerogenixX GmbH is a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

personalized cell therapyimmune toleranceorgan transplantationtolerogenic cell therapymodified immune cellsimmunosuppression reductionkidney transplantationclinical stage biopharmacell and gene therapydonor-specific toleranceCGTex-vivo cell therapyadvanced therapy medicinal productATMPautoimmune disease therapyregenerative medicineMIC technology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TolerogenixX GmbH Comparables

Compare TolerogenixX GmbH with similar companies based on industry and business-model similarity.

TolerogenixX GmbH comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Medeor Therapeutics
85%
Quell Therapeutics
78%
Cell4Cure AB
75%

TolerogenixX GmbH Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 6, 2023
SeedMay 23, 2017

TolerogenixX GmbH Investors

Notable investors and investment history

TolerogenixX GmbH investors
InvestorRounds
High-Tech GründerfondsSeries A, Seed
KalodionSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 152% MoM, reaching 2.3K.

  • Jul 24, 2026

    Monthly visitors increased 77% MoM.

Recent news

Latest coverage and updates

  • is_developingJun 29, 2026

    TolerogenixX GmbH is developing MIC-Lx.

TolerogenixX GmbH Filings

Explore SEC and related filing metadata, where available.

TolerogenixX GmbH filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about TolerogenixX GmbH's valuation, stock price, and market status.

Is TolerogenixX GmbH a public or private company?

TolerogenixX GmbH is a private company.

What is the current stock price of TolerogenixX GmbH?

TolerogenixX GmbH is a private company with no public stock price. No recent secondary market data is available.

How much is TolerogenixX GmbH worth (valuation)?

Valuation information for TolerogenixX GmbH is not publicly available.

Can I buy TolerogenixX GmbH stock?

TolerogenixX GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was TolerogenixX GmbH's last funding round?

TolerogenixX GmbH's most recent funding round was Series A on July 6, 2023.

Who are the main investors in TolerogenixX GmbH?

Key investors in TolerogenixX GmbH include High-Tech Gründerfonds.

Will TolerogenixX GmbH IPO soon?

No public IPO plans have been announced for TolerogenixX GmbH.

How can I track TolerogenixX GmbH secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor TolerogenixX GmbH's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHeidelberg
Employee Range3
Year Founded2016
Last FundingJul 6, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?